Inflammation in Alzheimer’s disease: insights from immunotherapy
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
More than 20 years after its initial formulation, the amyloid cascade hypothesis—which postulates that build-up of toxic amyloid-β species initiates a series of events that culminates in neurodegeneration and symptoms (Hardy and Higgins, 1992)—continues to dominate thinking on the pathogenesis of Alzheimer’s disease. Although the exact sequence of events linking amyloid-β accumulation to aggregation of hyperphosphorylated tau in different neuronal compartments, neuronal loss, synaptic dysfunction and symptoms remains unknown, there is now a substantial body of evidence implicating neuroinflammation in the pathogenesis of Alzheimer’s disease. Thus activated microglia accumulate around amyloid plaques both in the brains of individuals with Alzheimer’s disease and in transgenic mice, and have been implicated in promoting neurodegeneration (Akiyama et al., 2000). Imaging studies using the 11C-R-PK11195 PET ligand provide evidence that activated microglial accumulate in the vicinity of amyloid plaque pathology, and that activated microglial burden correlates with declining cognition (Edison et al., 2008). Genome-wide association studies have identified a number of risk variants for Alzheimer’s disease implicated in inflammatory responses (Bettens et al., 2013); exome sequencing has revealed polymorphisms in the microglial receptor TREM2 gene as a rare but significant risk for Alzheimer’s disease (Guerreiro et al., 2013; Jonsson et al., 2013); and recently, the CD33 risk allele has been shown to inhibit microglial clearance of amyloid-β (Bradshaw et al., 2013; Griciuc et al., 2013). Finally, an integrative network-based genetic analysis of Alzheimer’s disease brain has implicated disturbance in immune/microglial networks in the pathogenesis of the disease (Zhang et al., 2013). If inflammation, and microglial activation in particular, are core features of Alzheimer’s disease, the exact mechanisms involved, and the roles of the different inflammatory components are far less clear. Microglia—the predominant macrophage species within the brain—can express different cell-surface receptors and change morphology in response to changes in local environment thus becoming ‘activated’ in numerous ways (Perry et al., 2010). It is likely that in the Alzheimer’s disease brain some activated microglial species may, in certain circumstances, adopt a proinflammatory profile with deleterious effects, promoting neuronal and synaptic damage. Conversely, a microglial reaction initiated in response to, and promoting clearance of toxic amyloid-β species may confer protection. Given evidence that reductions in the rate of clearance of amyloid-β1–42 are seen in sporadic Alzheimer’s disease (Mawuenyega et al., 2010), it may be that subtle alterations in normal inflammatory-mediated clearance of fibrillar or perhaps oligomeric amyloid-β (Frenkel et al., 2013) play important roles in the earliest stages of Alzheimer’s disease pathogenesis. Targeting the inflammatory cascade in Alzheimer’s disease either to attenuate harmful effects or promote clearance of abnormal proteins is an attractive therapeutic option. To date, clinical trials of ‘anti-inflammatory’ drugs including non-steroidals and aspirin have yet to show definite benefits in Alzheimer’s disease (Jaturapatporn et al., 2012). After the remarkable demonstration that peripheral, active vaccination against amyloid-β1–42 leads to clearance of brain amyloid from the brains of transgenic mice carrying human Alzheimer’s disease mutations (Schenk et al., 1999) immunotherapy-based approaches aimed at promoting amyloid clearance have dominated attempts to modify the course of human Alzheimer’s disease over the last decade or so. The first such study in man (AN1792) was halted after 6% of those on active therapy developed significant brain inflammation (Gilman et al., 2005). Subsequently, none of a number of passive vaccination studies using a number of different agents all targeting slightly different parts of the amyloid-β1–42 protein has succeeded in reaching their primary, clinical end-points in pivotal trials (reviewed in Karran, 2012). Importantly, however, there is considerable evidence that these approaches are having immune/inflammatory-mediated effects within the human brain. Aside from the meningoencephalitis that complicated the original AN1792 trial (Fox et al., 2005), in several studies, and particularly in ApoE ε4 carriers, immunotherapy has been associated with ‘amyloid-related imaging abnormalities’—often asymptomatic and usually mild and reversible oedema/effusions (ARIA-E) or haemosiderin deposition (ARIA-H), that may reflect immune-related flux of amyloid pathology in/out of vessels (Sperling et al., 2011). Amyloid-β vaccination has been shown to alter Alzheimer’s disease biomarkers including levels of CSF tau (Blennow et al., 2012). Finally, significant reduction in brain amyloid-β pathology has been demonstrated in the few treated patients that have thus far come to post
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“, 2013); exome sequencing has revealed polymorphisms in the microglial receptor TREM2 gene as a rare but significant risk for Alzheimer’s disease (Guerreiro et al., 2013; Jonsson et al., 2013); and recently, the CD33 risk allele has been shown to inhibit microglial clearance of amyloid-b (Bradshaw et al.”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 2×
“Given evidence that reductions in the rate of clearance of amyloid-b1–42 are seen in sporadic Alzheimer’s disease (Mawuenyega et al., 2010), it may be that subtle alterations in normal inflammatory-mediated clearance of fibrillar or perhaps oligomeric amyloid-b (Frenkel et al.”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“Finally, an integrative network-based genetic analysis of Alzheimer’s disease brain has implicated disturbance in immune/microglial networks in the pathogenesis of the disease (Zhang et al., 2013).”
BackgroundMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 3×
“The influence of systemic inflammatory events on neurodegeneration remains to be clarified (Perry et al., 2010).”
BackgroundInfluentialHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 3×
“%) reductions in fibrillar amyloid-b42 load compared with those who did not receive treatment, demonstrating that, as previously reported (Holmes et al., 2008), peripheral vaccination against amyloid-b has clear and significant effects on its primary target within the brain.”
BackgroundResultInfluentialClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 2×
“(ARIA-H), that may reflect immune-related flux of amyloid pathology in/out of vessels (Sperling et al., 2011).”
BackgroundScavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
Khoury, J. E., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., & Loike, J. D. (1996) · Nature · doi:10.1038/382716a0 · Cited by 727 · cited 1×
“…widely throughout the cortex, clustering of activated microglia implicated in phagocytosis, i.e. those expressing macrophage scavenger-receptor A (El Khoury et al., 1996), was seen in the vicinity of amyloid plaques; and in the immunized group alone these clusters correlated with amyloid-b42 load.”
Background
Cited by
Dementia and Cognitive Impairment
Hugo, J., & Ganguli, M. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.001 · Cited by 902
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“Targeting inflammatory cascade in AD could reduce harmful effects and promote clearance of abnormal protein is an attractive target therapeutic option (Schott and Revesz, 2013).”
Apoptotic cell: linkage of inflammation and wound healing
Wu, Y.-S., & Chen, S.-N. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00001 · Cited by 500
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303
“There are many potential roles for inflammation in the pathogenesis of AD with one possibility being that Aβ deposition occurs independent of inflammatory processes, but that the type and extent of inflammatory response to Aβ deposition within the brain might trigger or influence subsequent neurodegeneration [36].”
BackgroundSelf-citationA study on the association between infectious burden and Alzheimer's disease
Bu, X. ‐., Yao, X. ‐., Jiao, S. ‐., Zeng, F., Liu, Y. ‐., Xiang, Y., Liang, C. ‐., Wang, Q. ‐., Wang, X., Cao, H. ‐., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12477 · Cited by 273
Metadata
- Authors
- Schott, J. M., & Revesz, T.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-26
- Volume
- 136
- Issue
- 9
- Pages
- 2654-2656
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1990992163
- Cited by
- 50
- References
- 17
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammation in Alzheimer’s disease: insights from immunotherapy. https://app.cochat.ai/papers/10.1093/brain/awt231
- The paper
- Schott, J. M., & Revesz, T. (2013). Inflammation in Alzheimer’s disease: insights from immunotherapy. Brain. https://doi.org/10.1093/brain/awt231
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.